You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 18, 2024

Supernus Pharms Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for SUPERNUS PHARMS, and what generic alternatives to SUPERNUS PHARMS drugs are available?

SUPERNUS PHARMS has three approved drugs.

There are twenty-six US patents protecting SUPERNUS PHARMS drugs. There is one tentative approval on SUPERNUS PHARMS drugs.

There are forty-six patent family members on SUPERNUS PHARMS drugs in ten countries and two supplementary protection certificates in two countries.

Summary for Supernus Pharms
International Patents:46
US Patents:26

Drugs and US Patents for Supernus Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-003 Oct 19, 2012 AB RX Yes Yes 7,910,131 ⤷  Sign Up ⤷  Sign Up
Supernus Pharms QELBREE viloxazine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 211964-003 Apr 2, 2021 RX Yes Yes 11,458,143 ⤷  Sign Up ⤷  Sign Up
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-003 Aug 16, 2013 AB1 RX Yes No 8,889,191 ⤷  Sign Up ⤷  Sign Up
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-001 Oct 19, 2012 AB RX Yes No 8,821,930 ⤷  Sign Up Y ⤷  Sign Up
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-001 Oct 19, 2012 AB RX Yes No 7,722,898 ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration
Paragraph IV (Patent) Challenges for SUPERNUS PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Capsules 25 mg, 50 mg, and 100 mg ➤ Subscribe 2014-05-12
➤ Subscribe Extended-release Capsules 200 mg ➤ Subscribe 2014-04-03
➤ Subscribe Extended-release Tablets 150 mg and 300 mg ➤ Subscribe 2013-04-12

Supplementary Protection Certificates for Supernus Pharms Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0138441 SPC/GB95/028 United Kingdom ⤷  Sign Up PRODUCT NAME: TOPIRAMATE; REGISTERED: UK 0242/0301 19950718
2317997 2190050-1 Sweden ⤷  Sign Up PRODUCT NAME: PHENTERMINE AND TOPIRAMATE; NAT. REG. NO/DATE: 59574-59577 20210617; FIRST REG.: IS IS/1/21/018/01-04 20210212
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.